Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum
BARCELONA, SPAIN and CAMBRIDGE MA.
Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, is scheduled to present at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum, being held February 23, 2016 at the New York Academy of Sciences in New York City.
Dr. Buesa’s presentation on the company’s strategy and development pipeline will take place on Tuesday, February 23rd 2016 at 14:55 pm EST. In addition, Dr. Buesa will also be a part of the Advances in Alzheimer’s Disease panel which will be held at 11:05 am EST.